MABS528MI
MilliporeSigma™ Mouse anti-HGPRT, Clone: 13H11.1,
Manufacturer: MilliporeSigma™
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | MABS528MI-Each-of-1 | In Stock | ₹ 40,292.08 |
MABS528MI - Each of 1
In Stock
Quantity
1
Base Price: ₹ 40,292.08
GST (18%): ₹ 7,252.574
Total Price: ₹ 47,544.654
Antigen
HGPRT
Classification
Monoclonal
Formulation
Purified mouse monoclonal IgG2bκ antibody in buffer containing 0.1M Tris-Glycine (pH 7.4), 150mM NaCl with 0.05% sodium azide.
Gene Symbols
HPRT1; HPRT
Immunogen
GST-tagged human HGPRT recombinant fragment lacking N- and C-terminal regions.
Quantity
100 μg
Research Discipline
Signaling
Gene ID (Entrez)
NP_000185
Content And Storage
Stable for one year at 2°C to 8°C from date of receipt.
Isotype
IgG2b κ
Applications
Western Blot
Clone
13H11.1
Gene Accession No.
P00492
Host Species
Mouse
Purification Method
Protein G Purified
Regulatory Status
RUO
Primary or Secondary
Primary
Target Species
Human
Form
Purified
Related Products
Description
- Specifically detects HGPRT clone: 13H11.1 in Human samples, and it is validated for Western Blotting Hypoxanthine-guanine phosphoribosyltransferase (EC:2.4.2.8; UniProt P00492; also known as HGPRT, HGPRTase) is encoded by the HPRT1 (also known as HGPRT, HPRT) gene (Gene ID 3251) in human
- HPRT is a purine salvage enzyme that catalyzes the condensation of 5-phosphoribosyl 1-pyrophosphate (PRPP) and hypoxanthine or guanine to form inosine 5-monophosphate (IMP) and guanosine 5-monophosphate (GMP), respectively
- PRPP is an essential compound for the de novo pathway of purine synthesis as well as the synthesis of pyrimidine compounds
- PRPP concentrations in erythrocyte are markedly increased in individuals with HPRT deficiency
- Complete HPRT deficiency leads to Lesch–Nyhan disease (LND) characterized by uric acid overproduction, motor dysfunction, cognitive disability, and self-injurious behavior
- Partial deficiency of HPRT activity causes Lesch–Nyhan variant (LNV) characterized by hyperuricemia and variable degree of neurological manifestations, depending on the residual enzyme activity.